AAD: Bimekizumab Response Durable at Four Years for Moderate-to-Severe Psoriasis
FRIDAY, March 15, 2024 -- Patients with psoriasis treated with bimekizumab rapidly achieve high levels of clinical and health-related quality-of-life responses that are durable at four years, according to research presented at the annual... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 15, 2024 Category: Pharmaceuticals Source Type: news

Short-Term High-Dose Psoriasis Therapy Shows Potential for Long-Term Disease Control
(MedPage Today) -- SAN DIEGO -- Short-term, high-dose treatment with risankizumab (Skyrizi) induced long-term control of plaque psoriasis in association with eradication of resident memory T cells (TRM), a small proof-of-principle study showed... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 13, 2024 Category: Dermatology Source Type: news

Investors put skin in Peninsula biotech's psoriasis game, and it delivers results
Alumis is now armed with a half-billion in cash and a wide range of targets, starting with psoriasis. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 12, 2024 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Home-Based Phototherapy for Psoriasis Matches Office Efficacy With Better QOL
(MedPage Today) -- SAN DIEGO -- Home-based phototherapy for psoriasis achieved outcomes similar to office-based therapy, suggesting a potential for more convenient, less expensive treatment for some patients, according to a study reported here... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 11, 2024 Category: Dermatology Source Type: news

Anti-IL-17, Anti-IL-23 Rxs Show Sustained Psoriasis Control Anti-IL-17, Anti-IL-23 Rxs Show Sustained Psoriasis Control
Both an approved anti-IL-17 therapy and an experimental oral anti-IL-23 therapy appeared to achieve relatively undiminished rates of psoriasis control in extension studies.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - March 11, 2024 Category: Dermatology Tags: Dermatology Source Type: news

Home- and Office-Based Phototherapy for Psoriasis Compared Home- and Office-Based Phototherapy for Psoriasis Compared
The multicenter LITE trial included 783 patients at 42 sites in the United States.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 10, 2024 Category: Consumer Health News Tags: Dermatology Source Type: news

Psoriasis Study Shows a Path for Considering US Drug Costs Psoriasis Study Shows a Path for Considering US Drug Costs
Only three of 13 psoriasis biologics appeared to be cost-effective based on US prices in a new analysis. The finding may aid policymakers struggling with drug price negotiations.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - March 8, 2024 Category: Dermatology Tags: Dermatology Source Type: news

Tacrolimus Microemulsion Has Good Efficacy, Safety for Scalp Psoriasis
TUESDAY, March 5, 2024 -- For scalp psoriasis, 0.1 percent tacrolimus microemulsion has good efficacy and safety, according to a study published online Feb. 12 in Dermatology and Therapy.Andreas Pinter, M.D., from the University Hospital Frankfurt... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 6, 2024 Category: Pharmaceuticals Source Type: news

New Data on First-Line Psoriasis Drug'Very Reassuring'New Data on First-Line Psoriasis Drug'Very Reassuring '
A higher cumulative dose of methotrexate taken did not increase the risk for liver fibrosis, but excess weight, metabolic syndrome, and diabetes did.Medscape News UK (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - March 1, 2024 Category: Dermatology Tags: Dermatology Source Type: news

Generic SpA Screening Tool Needed Across Comorbid Diseases Generic SpA Screening Tool Needed Across Comorbid Diseases
A comparison of screening tools for SpA in conditions that commonly co-occur with the disease revealed few screening tool options for patients with uveitis or IBD, compared with psoriasis.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 1, 2024 Category: Allergy & Immunology Tags: Rheumatology Source Type: news

What Drives Fatigue in Psoriasis and PsA? What Drives Fatigue in Psoriasis and PsA?
Joint pain and itch were key culprits, according to a cross-sectional analysis of Danish data.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 27, 2024 Category: Dermatology Tags: Dermatology Source Type: news

Biologic Treatment for Psoriasis Linked to Lower Mortality Biologic Treatment for Psoriasis Linked to Lower Mortality
Evidence to support the hypothesis that the use of systemic immunomodulatory agents for psoriasis " quenches systemic inflammation and potentially improves " survival is limited, investigators said.MDedge News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 26, 2024 Category: Cardiology Tags: Dermatology Source Type: news

Doctor shares key symptoms of genital psoriasis - and who is at risk
While psoriasis tends to mainly target your elbows, knees, scalp and lower back, it could also appear on your genitals, a medical expert has warned. (Source: Daily Express - Health)
Source: Daily Express - Health - February 24, 2024 Category: Consumer Health News Source Type: news

EMA Approves Tx for Psoriasis and Other Autoimmune Disorders EMA Approves Tx for Psoriasis and Other Autoimmune Disorders
The biosimilar Pyzchiva is highly similar to Stelara, which was approved in the EU in 2009.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 23, 2024 Category: Dermatology Tags: Dermatology Source Type: news

Tapinarof Under FDA Review for Treating Atopic Dermatitis Tapinarof Under FDA Review for Treating Atopic Dermatitis
Approved in 2022 for psoriasis, the manufacturer has submitted an application for approval of tapinarof cream for treating atopic dermatitis in adults and children 2 years of age and older.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 16, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news